Skip to main content
Publications
Fernandez-Barres S, Romaguera D, Valvi D, Martinez D , Vioque J, Navarrete-Munoz EM, Amiano P, Gonzalez-Palacios S, Guxens M, Pereda E, Riano I, Tardon A, Iniguez C, Arija V, Sunyer J, Vrijheid M, INMA Project. Mediterranean dietary pattern in pregnant women and offspring risk of overweight and abdominal obesity in early childhood: the INMA birth cohort study . Pediatr Obes. 2016 Dec;11(6):491-9. doi: 10.1111/ijpo.12092
Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, Nombela-Franco L, Cheema A, Kefer J, Gutierrez E, Benitez LM, Amat-Santos IJ, Serra V, Eltchaninoff H, Alnasser SM, Elizaga J, Dager A, Garcia Del Blanco B, Ortas-Nadal MDR, Marsal JR , Campelo-Parada F, Regueiro A, Del Trigo M, Dumont E, Puri R, Rodes-Cabau J. Reply: antithrombotic regimen in post-TAVR atrial fibrillation: not an easy decision . JACC Cardiovasc Interv. 2016 Nov 28;9(22):2366-8. doi: 10.1016/j.jcin.2016.09.038
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B , Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab provides better relief from psoriasis-related pain, itching, and scaling than ustekinumab . Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides better relief from quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides better relief from quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B , Williams N, Fox T, Augustin M. Secukinumab provides faster and better quality of life impact than ustekinumab in psoriasis . Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 10, 2016. Las Vegas, NV.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the SDPA 14th Annual Fall Dermatology Conference 2016; November 6, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the SDPA 14th Annual Fall Dermatology Conference 2016; November 6, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Balp M, Abuzakouk M, Berard F, Canonica GW, Gimenez-Arnau A, Hollis K , Khalil S, Knulst A, Lacour J, Lynde C, Marsland A, Maurer M, McBride D, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink J, Proctor C, Sussman G, Weller K, Grattan C. Comparison of direct healthcare costs associated with chronic spontaneous/idiopathic urticaria in 7 countries - results from the ASSURE-CSU study . Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A565.
Hollis K , Abuzakouk M, Balp M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Khalil S, Knulst AC, Lacour J, Lynde C, Maurer M, McBride D, Nakonechna A, Ortiz De Frutos J, Oude Elberink J, Proctor C, Sussman G, Sweeney C, Tian H, Weller K, Marsland A. Assessing health-utility values for chronic spontaneous/idiopathic urticaria in real-world using the EQ-5D: results from ASSURE-CSU study . Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A570-1.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B , Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab . Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 20, 2016. Las Vegas, NV. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.
Blauvelt A, Korman N, Mollon P, Zhou Y, Milutinovic M, You R, Sherif B , Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality of life impact than ustekinumab in subjects with moderate to severe plaque psoriasis . Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 20, 2016. Las Vegas, NV. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.
Mease P, Schwab PE , Dinh H, Sheer R, Cappelleri J, Bananis E, Harnett J, Hsu MA. Treatment patterns, health care resource utilization, and costs associated with psoriatic arthritis among Humana commercial and Medicare member populations . Poster presented at the 2016 Academy of Managed Care Pharmacy's 28th Annual Meeting & Expo; October 3, 2016. National Harbor, MD.
Police RL, Trask PC, Wang J, Olivares R, Khan S , Abbe A, Colosia A , Njue A , Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis . J Oncol Pharm Pract. 2016 Oct;22(5):666-78. doi: 10.1177/1078155215603230
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Vender R, Leonardi C, Puig L, Ziv M, Zhou Y, Gilloteau I, Sherif B , McLeod LD , Nyirady J, Guana A, Strober B. Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: an area under the curve analysis . Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Blauvelt A, Mehlis S, Vanaclocha F, Vender R, Zhao Y, Gilloteau I, Davenport E , Williams N, Guana A, Tyring S. Secukinumab provides greater 52-week sustained relief from dermatology-related quality of life impact on clothing choice and sexual function than ustekinumab . Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA , Buaron SK, Kirby SY, Pascoe SJ. Safety of adding salmeterol to fluticasone propionate in children with asthma . N Engl J Med. 2016 Sep 1;375(9):840-9. doi: 10.1056/NEJMoa1606356
Afonso A, Schmiedl S, Becker C, Tcherny-Lessenot S, Primatesta P, Plana E , Souverein P, Wang Y, Korevaar JC, Hasford J, Reynolds R, de Groot MC, Schlienger R, Klungel O, Rottenkolber M. A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction . Eur J Clin Pharmacol. 2016 Sep;72(9):1105-16.
Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, Nombela-Franco L, Cheema A, Kefer J, Gutierrez E, Benitez LM, Amat-Santos IJ, Serra V, Eltchaninoff H, Alnasser SM, Elizaga J, Dager A, Garcia Del Blanco B, Ortas-Nadal Mdel R, Marsal JR , Campelo-Parada F, Regueiro A, Del Trigo M, Dumont E, Puri R, Rodes-Cabau J. Warfarin and antiplatelet therapy versus Warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement . JACC Cardiovasc Interv. 2016 Aug 22;9(16):1706-17. doi: 10.1016/j.jcin.2016.06.025
O'Connor G, Pinero Casas M, Basagana X, Vicente ML, Davand P, Torrent M, Martinez-Murciano D , Garcia-Esteban R , Marinelli M, Sunyer J, Julvez J. Television viewing duration during childhood and long-association with adolescent neuropsychological outcomes . Prev Med Rep. 2016 Aug 15;4:447-52. doi: 10.1016/j.pmedr.2016.08.013
Zografos LJ , Suzart K, Horvat-Broecker A, Soriano-Gabarro M, Wolin DL , Calingaer B , Davenport EK , Hollis KA , Andrews E. Evaluating physician knowledge of risks and safe use of Xarelto (rivaroxaban) . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):288-9.
Nabhan C, Zhou X , Day BM, Dawson K, Zelenetz AD, Friedberg JW, Cerhan JR, Link BK, Flowers CR. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States . Am J Hematol. 2016 Aug;91(8):770-5. doi: 10.1002/ajh.24401
Plana E , McGrath LJ, Fortuny J , Ruigomez A, Fernandez-Cantero O, Garcia-Rodriguez LA, Gilsenan AW , Andrews E, Rebordosa C , Ziemiecki R . An algorithm to identify duplicate patients when pooling aggregate data from two primary care databases in the United Kingdom . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58-9. doi: 10.1002/pds
Robinson O, Martinez D , Aurrekoetxea JJ, Estarlich M, Somoano AF, Iniguez C, Santa-Marina L, Tardon A, Torrent M, Sunyer J, Valvi D, Vrijheid M. The association between passive and active tobacco smoke exposure and child weight status among Spanish children . Obesity (Silver Spring). 2016 Aug;24(8):1767-77. doi: 10.1002/oby.21558
Manzano-Salgado CB, Casas M, Lopez-Espinosa MJ, Ballester F, Martinez D , Ibarluzea J, Santa-Marina L, Schettgen T, Vioque J, Sunyer J, Vrijheid M. Variability of perfluoroalkyl substance concentrations in pregnant women by socio-demographic and dietary factors in a Spanish birth cohort . Environ Int. 2016 Jul;92-93:357-65. doi: 10.1016/j.envint.2016.04.004